Achieve Life Sciences up on positive trial data for vaping cessation treatment

Achieve Life Sciences

20/04/2023 14:15

** Drug developer Achieve Life Sciences Inc's  ACHV.O  shares
up 3.6% at $7.30 premarket
    ** Company says its experimental treatment, Cytisinicline,
in mid-stage trial showed statistically significant vaping
cessation benefit for treated participants
    ** Trial enrolled 160 adults who use e-cigarettes or
nicotine vapes and who do not currently smoke cigarettes,
testing safety and efficacy of 3 mg dose, given three times
daily for 12 weeks vs placebo - ACHV
    ** 12-week treatment showed 2.6 times better quit rates
during last 4 weeks of treatment vs subjects on placebo, company
says 
    ** Vaping cessation rate during 9 and 12 weeks was 31.8% for
cytisinicline vs 15.1% for placebo - ACHV
    ** Company plans to report top-line results in Q2 2023 from
late-stage trial for Cytisinicline as new smoking cessation
treatment
    ** As of last close, company's shares have more than doubled
YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com))